IPO registrations (S-1, F-1) · Registrants
STANDARD BIOTOOLS INC.
- SEC CIK
- 1162194 · filings on EDGAR ↗
- Name on the registration
- FLUIDIGM CORP
- Former names
- FLUIDIGM CORP (2002–2022)
- Registration
- Form S-1, first filed 2008-04-14, last 2011-02-09; 2 initial registrations, 17 amendments
- Outcome
- Final prospectus filed 2011-02-10; declared effective 2011-02-09; withdrawal requested 2008-09-26
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 50 MILK STREET, 10TH FLOOR, Boston, MA 02109
- EIN
- 77-0513190
- Ticker
- LAB (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- STANDARD BIOTOOLS INC. on the corporate pages
Offering terms
- Proposed price range
- $13.50–$15.50 per share (S-1/A filed 2011-02-09)
- Final price
- $13.50 per share, within the range (424B1 filed 2011-02-10, an initial public offering)
- Shares sold
- 5,558,333
- Gross proceeds
- $75,037,495 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol FLDM
- Lead underwriters
- Deutsche Bank
- Syndicate
- Piper Sandler; Cowen; Leerink Partners; December 31 (2,009); respectively) (4,706)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: Standard BioTools Inc. Fuzzy (name and state)
- Business registration: STANDARD BIOTOOLS INC. Fuzzy (name and state)
- Business registration: STANDARD BIOTOOLS INC. Fuzzy (name and state)
- Business registration: STANDARD BIOTOOLS INC. Fuzzy (name and state)
- Form 5500 plan sponsor: STANDARD BIOTOOLS INC. EXACT (EIN (EXACT))
- Form D issuer: FLUIDIGM CORP EXACT (CIK (EXACT))
- SEC filer: FLUIDIGM CORP EXACT (CIK (EXACT))
- Person page: Ole Andreas Halvorsen Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwner))
- Person page: Thomas D Carey Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 25
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2008-04-14 | S-1 | S-1 (registration) | FLUIDIGM CORP | 0000950134-08-006517 ↗ |
| 2008-05-27 | S-1/A | S-1/A (amendment) | FLUIDIGM CORP | 0000950134-08-010232 ↗ |
| 2008-05-30 | S-1/A | S-1/A (amendment) | FLUIDIGM CORP | 0000891618-08-000292 ↗ |
| 2008-07-07 | S-1/A | S-1/A (amendment) | FLUIDIGM CORP | 0000950134-08-012379 ↗ |
| 2008-07-18 | S-1/A | S-1/A (amendment) | FLUIDIGM CORP | 0000950134-08-012942 ↗ |
| 2008-08-13 | S-1/A | S-1/A (amendment) | FLUIDIGM CORP | 0000950134-08-015087 ↗ |
| 2008-08-27 | S-1/A | S-1/A (amendment) | FLUIDIGM CORP | 0000950134-08-015833 ↗ |
| 2008-09-05 | S-1/A | S-1/A (amendment) | FLUIDIGM CORP | 0000950134-08-016209 ↗ |
| 2008-09-15 | S-1/A | S-1/A (amendment) | FLUIDIGM CORP | 0000950134-08-016569 ↗ |
| 2008-09-17 | S-1/A | S-1/A (amendment) | FLUIDIGM CORP | 0000950134-08-016723 ↗ |
| 2008-09-18 | S-1/A | S-1/A (amendment) | FLUIDIGM CORP | 0000950134-08-016803 ↗ |
| 2008-09-22 | S-1/A | S-1/A (amendment) | FLUIDIGM CORP | 0000950134-08-016945 ↗ |
| 2008-09-26 | RW | RW (withdrawal request) | FLUIDIGM CORP | 0000950134-08-017178 ↗ |
| 2008-10-07 | RW | RW (withdrawal request) | FLUIDIGM CORP | 0000950134-08-017657 ↗ |
| 2010-12-03 | S-1 | S-1 (registration) | FLUIDIGM CORP | 0001193125-10-273807 ↗ |
| 2011-01-07 | S-1/A | S-1/A (amendment) | FLUIDIGM CORP | 0001193125-11-003819 ↗ |
| 2011-01-18 | S-1/A | S-1/A (amendment) | FLUIDIGM CORP | 0001193125-11-008513 ↗ |
| 2011-01-28 | S-1/A | S-1/A (amendment) | FLUIDIGM CORP | 0001193125-11-016501 ↗ |
| 2011-02-02 | S-1/A | S-1/A (amendment) | FLUIDIGM CORP | 0001193125-11-022042 ↗ |
| 2011-02-07 | S-1/A | S-1/A (amendment) | FLUIDIGM CORP | 0001193125-11-025233 ↗ |
| 2011-02-09 | S-1/A | S-1/A (amendment) | FLUIDIGM CORP | 0001193125-11-028760 ↗ |
| 2011-02-09 | EFFECT | EFFECT (declared effective) | FLUIDIGM CORP | 9999999995-11-000385 ↗ |
| 2011-02-10 | S-1MEF | S-1MEF (added securities) | FLUIDIGM CORP | 0001193125-11-029728 ↗ |
| 2011-02-10 | 424B1 | 424B1 (final prospectus) | FLUIDIGM CORP | 0001193125-11-030835 ↗ |
| 2012-05-10 | EFFECT | EFFECT (declared effective) | FLUIDIGM CORP | 9999999995-12-001509 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2011-02-09 | S-1/A | registration statement | $13.50–$15.50 | $8.37 | 5,172,414 | $43,293,105 | Nasdaq FLDM | 6 | primary document; range, price line, shares headline, proceeds computed, underwriting table 2, cover names 4 | document ↗ |
| 2011-02-10 | 424B1 | final prospectus | $13.50 | 5,558,333 | $75,037,495 | Nasdaq FLDM | 6 | primary document; price sentence, shares headline, proceeds table, underwriting table 2, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| COLELLA SAMUEL D | Director | 37 | 2011–2020 | ||
| EuclidSR Biotechnology Partners, L.P. | TenPercentOwner | 2 | 2011 | ||
| EuclidSR Partners, L.P. | TenPercentOwner | 2 | 2011 | ||
| JOG VIKRAM | Officer | Chief Financial Officer; CHIEF FINANCIAL OFFICER | 99 | 2011–2023 | |
| JONES ROBERT C | Officer | EVP, Research & Development; EVP, RESEARCH & DEVELOPMENT; Exec. VP, Research & Dev.; See Remarks | 46 | 2011–2016 | |
| Loh Jeremy | Director | 2 | 2011 | ||
| NUSSBACHER KENNETH J | Director | 3 | 2011 | ||
| Smith William Maxwell | Officer | EVP, Legal Affairs; EVP, Legal Affairs & GC; EVP, LEGAL AFFAIRS & GC; See General Remarks; see remarks; See Remarks; VP, Legal Affairs & GC; VP, LEGAL AFFAIRS & GC | 69 | 2011–2016 | |
| VERSANT AFFILIATES FUND I-A LP | TenPercentOwner | 4 | 2011 | ||
| VERSANT AFFILIATES FUND I-B LP | TenPercentOwner | 4 | 2011 | ||
| VERSANT SIDE FUND I LP | TenPercentOwner | 4 | 2011 | ||
| VERSANT VENTURE CAPITAL I LP | TenPercentOwner | 4 | 2011 | ||
| Walder Fredric T | Officer | Chief Business Officer; CHIEF BUSINESS OFFICER; CHIEF OPERATING OFFICER; See Remarks | 19 | 2011–2015 | |
| Whitaker Raymond J | Director | 2 | 2011 | ||
| Worthington Gajus Vincent | Director,Officer; Officer; Other | CHIEF EXECUTIVE OFFICER; President & CEO; PRESIDENT & CEO; President, CEO and Director | 70 | 2011–2016 | |
| YOUNG JOHN A | Director | 9 | 2011–2017 | ||
| Yow Mai Chan | Officer | See Remarks; VP, WW Mfg & MD-Singapore | 38 | 2011–2018 | |
| Biomedical Sciences Investment Fund Pte Ltd. | TenPercentOwner | 2 | 2011 | ||
| EDB Investments Pte Ltd. | TenPercentOwner | 2 | 2011 | ||
| SINGAPORE BIO INNOVATIONS PTE LTD | TenPercentOwner | 2 | 2011 | ||
| JONES PATRICK S | Director | 12 | 2011–2019 | ||
| JONES EVAN/ FA | Director; Director,TenPercentOwner | 22 | 2011–2017 | ||
| Burbach Gerhard F | Director | 17 | 2013–2022 | ||
| McPhail Steven | Officer | Chief Commercial Officer; GM, PRODUCTION GENOMICS | 24 | 2015–2019 | |
| UNGER MARC | Officer | EVP, R&D and Marketing; See Remarks | 8 | 2015–2016 | |
| LEE JENNIFER LING | Officer | See Remarks | 8 | 2016–2018 | |
| Khadder Nicholas | Officer | See Remarks; SVP, Gen. Counsel & Secretary | 29 | 2016–2022 | |
| Linthwaite Stephen Christopher | Officer | President & CEO; President & COO | 33 | 2016–2022 | |
| Bi-Directional Disequilibrium Fund, L.P. | TenPercentOwnerOther | 84 | 2016–2019 | ||
| LCS Event Partners, LLC | TenPercentOwnerOther | 79 | 2016–2018 | ||
| LCS, LLC | TenPercentOwnerOther | 65 | 2016–2019 | ||
| LCS L/S, LLC | TenPercentOwnerOther | 79 | 2016–2018 | ||
| Levcap Alternative Fund, L.P. | Other; TenPercentOwnerOther | 78 | 2016–2018 | ||
| Levin Capital Strategies GP, LLC | TenPercentOwnerOther | 84 | 2016–2019 | ||
| LEVIN CAPITAL STRATEGIES, L.P. | TenPercentOwnerOther | 94 | 2016–2019 | ||
| Safinia Partners, L.P. | TenPercentOwnerOther | 78 | 2016–2018 | ||
| LEVIN JOHN A | TenPercentOwnerOther | 83 | 2016–2019 | ||
| BARTHELEMY NICOLAS | Director | 22 | 2017–2022 | ||
| Paya Carlos V | Director | 19 | 2017–2023 | ||
| Kreger Bradley Allen | Officer | SVP, Global Operations | 19 | 2018–2022 | |
| Clague Laura | Director | 8 | 2018–2023 | ||
| Crate Darrell W | TenPercentOwnerOther | 11 | 2019 | ||
| Kalichstein Avshalom | TenPercentOwnerOther | 11 | 2019 | ||
| LE Partners Holdings III LLC | TenPercentOwnerOther | 11 | 2019 | ||
| LE Partners Holdings II LLC | TenPercentOwnerOther | 11 | 2019 | ||
| LE Partners Holdings IV LLC | TenPercentOwnerOther | 11 | 2019 | ||
| LE Partners Holdings LLC | TenPercentOwnerOther | 11 | 2019 | ||
| Levin Easterly Partners LLC | TenPercentOwnerOther | 11 | 2019 | ||
| Murphy John W | TenPercentOwnerOther | 11 | 2019 | ||
| McCracken Colin | Officer | Chief Commercial Officer | 16 | 2019–2022 | |
| Colston Bill | Director | 6 | 2019–2022 | ||
| Stankovic Ana K. | Director | 3 | 2020–2021 | ||
| Caligan Partners LP | TenPercentOwner; TenPercentOwnerOther | 11 | 2021–2023 | ||
| JOHNSON DAVID EDWARD | TenPercentOwner | 10 | 2021–2023 | ||
| Casdin Capital, LLC | Director,TenPercentOwner | 28 | 2022–2025 | ||
| Casdin Eli | Director; Director,TenPercentOwner | 36 | 2022–2026 | ||
| Casdin Partners GP, LLC | Director,TenPercentOwner | 28 | 2022–2025 | ||
| Casdin Partners Master Fund, L.P. | Director; Director,TenPercentOwner | 28 | 2022–2025 | ||
| Casdin Private Growth Equity Fund II GP, LLC | Director; Director,TenPercentOwner | 28 | 2022–2025 | ||
| Casdin Private Growth Equity Fund II, L.P. | Director; Director,TenPercentOwner | 28 | 2022–2025 | ||
| Davis Jeremy Steven | Officer | SVP Chief Commercial Officer | 4 | 2022–2023 | |
| Egholm Michael | Director,Officer | President & CEO | 23 | 2022–2026 | |
| Kim Hanjoon Alex | Officer | Chief Financial Officer; Chief Operating Officer | 19 | 2022–2026 | |
| Madaus Martin D | Director | 6 | 2022–2023 | ||
| Witney Frank | Director | 7 | 2022–2026 | ||
| ELOI FENEL M | Director | 6 | 2023–2026 | ||
| Black Jeffrey G. | Officer | SVP & Chief Financial Officer | 7 | 2023–2024 | |
| Casdin Partners FO1-MSV, LP | Director | 9 | 2023–2024 | ||
| Carey Thomas D. | Director | 7 | 2024–2026 | person page Fuzzy | |
| CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC | Director | 25 | 2024–2025 | ||
| Casdin Private Growth Equity Fund, L.P. | Director | 25 | 2024–2025 | ||
| Cox Troy | Director | 8 | 2024–2026 | ||
| HIBBS KATHY L | Director | 5 | 2024–2026 | ||
| HALVORSEN OLE ANDREAS | TenPercentOwner | 1 | 2024 | person page Fuzzy | |
| Ott David C. | TenPercentOwner | 1 | 2024 | ||
| Shabet Rose Sharon | TenPercentOwner | 1 | 2024 | ||
| VIKING GLOBAL INVESTORS LP | TenPercentOwner | 1 | 2024 | ||
| Viking Global Opportunities GP LLC | TenPercentOwner | 1 | 2024 | ||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | TenPercentOwner | 1 | 2024 | ||
| Viking Global Opportunities Parent GP LLC | TenPercentOwner | 1 | 2024 | ||
| Viking Global Opportunities Portfolio GP LLC | TenPercentOwner | 1 | 2024 | ||
| Casdin Amplify Fund, LP | Director; TenPercentOwner | 10 | 2024–2025 | ||
| Mackay Sean | Officer | SVP & Chief Business Officer | 12 | 2024–2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2014-02-28 | FLUIDIGM CORP | Biotechnology | $76,804,578 | $76,804,578 | 24 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Investment adviser | BEACON ASSET MANAGEMENT | MA | Investment advisers (Form ADV) | same street address and ZIP code, 50 MILK ST 10TH FL 02109 (FUZZY: a shared address, not proof of a shared organization) |
| Business registration | Standard BioTools Inc. | MA | State business registries | name and state |
| Business registration | STANDARD BIOTOOLS INC. | MA | State business registries | name and state |
| Business registration | STANDARD BIOTOOLS INC. | MA | State business registries | name and state |
| Business registration | STANDARD BIOTOOLS INC. | MA | State business registries | name and state |
| Form D issuer | FLUIDIGM CORP | CA | Form D private offerings | CIK (EXACT) |
| SEC filer | STANDARD BIOTOOLS INC. | SEC filers (EDGAR) | CIK (EXACT) | |
| Form 5500 plan sponsor | STANDARD BIOTOOLS INC. | EIN (EXACT) | ||
| Person page | Ole Andreas Halvorsen | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwner) | |
| Person page | Thomas D Carey | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, MA first:
- ERGO SCIENCE CORP MA
- MILLENNIUM PHARMACEUTICALS INC MA
- ESSENTIAL THERAPEUTICS INC MA
- ARQULE INC MA
- ASCENT PEDIATRICS INC MA
- EPIX Pharmaceuticals, Inc. MA
- PRAECIS PHARMACEUTICALS INC MA
- PARATEK PHARMACEUTICALS INC MA
- PREDIX PHARMACEUTICALS HOLDINGS INC MA
- CervoMed Inc. MA
In other datasets, the same topic (Health) in MA:
- Nonprofit: ABBIE M GRIFFIN HOSPITAL FUND (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health